Drugs / Investigational Influenza Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06821061 | Feb → Dec 2025 | COVID-19, influenza | BioNTech SE | Completed | No outcome recorded |
| Phase 1/2 | NCT06683352 | Nov 2024 → Jul 2025 | COVID-19, influenza | BioNTech SE | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06178991 Comparator | Dec 2023 → Nov 2024 | COVID-19, influenza | BioNTech SE | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Investigational Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06821061 ↗ |
| Modality | Vaccine | “Investigational influenza vaccine” NCT06178991 ↗ |